IO Biotech Inc has a consensus price target of $9.8, established from looking at the 12 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler on May 15, 2024, March 6, 2024, and September 28, 2023. With an average price target of $10 between HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler, there's an implied 669.23% upside for IO Biotech Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/15/2024 | Buy Now | 823.08% | HC Wainwright & Co. | Emily Bodnar | $8 → $12 | Maintains | Buy | Get Alert |
03/06/2024 | Buy Now | 515.38% | HC Wainwright & Co. | Emily Bodnar | → $8 | Reiterates | Buy → Buy | Get Alert |
09/28/2023 | Buy Now | 669.23% | Piper Sandler | Christopher Raymond | → $10 | Initiates | → Overweight | Get Alert |
09/13/2023 | Buy Now | 515.38% | HC Wainwright & Co. | Emily Bodnar | → $8 | Reiterates | Buy → Buy | Get Alert |
08/15/2023 | Buy Now | 438.46% | Morgan Stanley | Matthew Harrison | $11 → $7 | Maintains | Overweight | Get Alert |
08/11/2023 | Buy Now | 515.38% | HC Wainwright & Co. | Emily Bodnar | $11 → $8 | Reiterates | Buy → Buy | Get Alert |
03/15/2023 | Buy Now | 669.23% | HC Wainwright & Co. | Emily Bodnar | → $10 | Reiterates | → Buy | Get Alert |
01/24/2023 | Buy Now | 746.15% | Morgan Stanley | Matthew Harrison | $15 → $11 | Maintains | Overweight | Get Alert |
11/21/2022 | Buy Now | 669.23% | HC Wainwright & Co. | Emily Bodnar | → $10 | Initiates | → Buy | Get Alert |
11/30/2021 | Buy Now | 1515.38% | Morgan Stanley | Matthew Harrison | — | Initiates | → Overweight | Get Alert |
11/30/2021 | Buy Now | — | Cowen & Co. | Yaron Werber | — | Initiates | → Outperform | Get Alert |
11/30/2021 | Buy Now | 1438.46% | Jefferies | Chris Howerton | — | Initiates | → Buy | Get Alert |
The latest price target for IO Biotech (NASDAQ: IOBT) was reported by HC Wainwright & Co. on May 15, 2024. The analyst firm set a price target for $12.00 expecting IOBT to rise to within 12 months (a possible 823.08% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for IO Biotech (NASDAQ: IOBT) was provided by HC Wainwright & Co., and IO Biotech maintained their buy rating.
There is no last upgrade for IO Biotech.
There is no last downgrade for IO Biotech.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IO Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IO Biotech was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
While ratings are subjective and will change, the latest IO Biotech (IOBT) rating was a maintained with a price target of $8.00 to $12.00. The current price IO Biotech (IOBT) is trading at is $1.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.